JPWO2021007277A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021007277A5
JPWO2021007277A5 JP2022500582A JP2022500582A JPWO2021007277A5 JP WO2021007277 A5 JPWO2021007277 A5 JP WO2021007277A5 JP 2022500582 A JP2022500582 A JP 2022500582A JP 2022500582 A JP2022500582 A JP 2022500582A JP WO2021007277 A5 JPWO2021007277 A5 JP WO2021007277A5
Authority
JP
Japan
Prior art keywords
compound
linker
agonist
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022500582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539804A (ja
JP2022539804A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/041120 external-priority patent/WO2021007277A1/en
Publication of JP2022539804A publication Critical patent/JP2022539804A/ja
Publication of JPWO2021007277A5 publication Critical patent/JPWO2021007277A5/ja
Publication of JP2022539804A5 publication Critical patent/JP2022539804A5/ja
Pending legal-status Critical Current

Links

JP2022500582A 2019-07-08 2020-07-08 線維性疾患状態およびがんの治療および予防のための化合物ならびに方法 Pending JP2022539804A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962871686P 2019-07-08 2019-07-08
US62/871,686 2019-07-08
US201962872146P 2019-07-09 2019-07-09
US62/872,146 2019-07-09
PCT/US2020/041120 WO2021007277A1 (en) 2019-07-08 2020-07-08 Compounds and methods for the treatment and prevention of fibrotic disease states and cancer

Publications (3)

Publication Number Publication Date
JP2022539804A JP2022539804A (ja) 2022-09-13
JPWO2021007277A5 true JPWO2021007277A5 (https=) 2023-07-14
JP2022539804A5 JP2022539804A5 (https=) 2023-07-14

Family

ID=74114231

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022500582A Pending JP2022539804A (ja) 2019-07-08 2020-07-08 線維性疾患状態およびがんの治療および予防のための化合物ならびに方法

Country Status (7)

Country Link
US (2) US12397059B2 (https=)
EP (1) EP3996715A4 (https=)
JP (1) JP2022539804A (https=)
CN (2) CN114269346A (https=)
AU (1) AU2020310141A1 (https=)
CA (1) CA3145908A1 (https=)
WO (1) WO2021007277A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022271866A1 (en) * 2021-05-14 2023-12-07 Purdue Research Foundation Folate receptor-targeted conjugates with brush border membrane enzyme-cleavable linkers and methods of use in imaging and treating cancer
CN116947658B (zh) * 2023-07-28 2025-10-28 南通华祥医药科技有限公司 一种1-氨基-2-甲基-2-丙醇的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142202A1 (en) * 2000-12-08 2006-06-29 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
KR20040053136A (ko) * 2001-09-28 2004-06-23 펄듀 리서치 파운데이션 리간드-면역원 공액체를 이용한 치료 방법
WO2007093901A1 (en) * 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
US20170266303A1 (en) 2014-11-25 2017-09-21 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
WO2017205661A1 (en) * 2016-05-25 2017-11-30 Purdue Research Foundation Method of treating cancer by targeting myeloid-derived suppressor cells
CN115916342A (zh) * 2020-07-08 2023-04-04 普渡研究基金会 用于治疗纤维化疾病和癌症的化合物、组合物和方法

Similar Documents

Publication Publication Date Title
US8609706B2 (en) Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
CN101843897B (zh) 治疗脱髓鞘疾病的鞘氨醇-1-磷酸受体激动剂
JP2004517049A5 (https=)
DK2326329T3 (en) Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
JP2019503365A5 (https=)
JP2006523216A5 (https=)
RU2010126063A (ru) Производные 4-(2-амино-1-гидроксиэтил)фенола как агонисты в2 адренергического рецептора
TW201808345A (zh) 聚乙二醇化卡非佐米化合物
US11844780B2 (en) Chlorinated tetralin compounds and pharmaceutical compositions
JP2006523214A5 (https=)
JP2021534160A5 (https=)
JP2006508965A5 (https=)
RU2002130247A (ru) Производные оксадиазола, обладающие противоопухолевым действием
JP2025118775A5 (https=)
JPWO2021093839A5 (https=)
JPWO2021007277A5 (https=)
CA2635093A1 (en) Derivatives of sulindac, use thereof and preparation thereof
RU2007105582A (ru) Агонисты рецепторов никотина и способы их применения для лечения воспалительных заболеваний
US8642580B2 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and platinum derivatives
JP2008519763A5 (https=)
JP2019525924A5 (https=)
US20160143914A1 (en) Nanoparticles for Encapsulation and Delivery of Bioactive Compounds and Compositions Thereof
JP2007519701A5 (https=)
EP4706656A1 (en) Combination therapy of dacomitinib and nintedanib for prevention or treatment of pulmonary fibrosis
CN121419775A (zh) 用于预防或治疗肺纤维化的培西达替尼和尼达尼布的联合疗法